The iron chelator deferoxamine decreases myeloma cell survival

• Published in: Journal of international medical research 2021-01, Vol.49 (1), p.300060520987396-300060520987396
• Main Authors: Yang, Feifei, Wu, Zhaoxian, Dai, Dan, Zhang, Lei, Zhang, Xiuqun, Zhang, Xuezhong, Xu, Yanli
• Format: Article
• Language: English
• Subjects: Apoptosis; Cell Survival; Deferoxamine - pharmacology; Deferoxamine - therapeutic use; Humans; Iron; Iron Chelating Agents - pharmacology; Iron Chelating Agents - therapeutic use; Multiple myeloma; Multiple Myeloma - drug therapy; Retrospective Clinical Research Report
• ISSN: 0300-0605; 1473-2300
• DOI: 10.1177/0300060520987396

Objective This study evaluated serum ferritin (SF) levels and investigated their relationships with various clinical markers in patients with multiple myeloma (MM). Furthermore, the effects and molecular mechanism of deferoxamine (DFO) in myeloma cells were studied. Methods Clinical data from 84 patients with MM were collected to evaluate SF content and its relationship with several important clinical parameters. MM1S and MM1R myeloma cells were chosen to investigate the effects of iron and DFO on cell survival and apoptosis. Results Increased SF levels were detected in newly diagnosed patients, especially those with stage III disease or the κ isotype. SF content was positively correlated with β2-microglobulin, interleukin-6, and lactate dehydrogenase expression. Furthermore, patients with progressive or relapsed disease had higher SF levels. Importantly, iron chelation with DFO efficiently inhibited myeloma cell survival and accelerated apoptosis by regulating apoptosis-related genes. Conclusions The importance of SF for MM was highlighted. Additionally, it is suggested that DFO may be a good therapeutic option for MM.